ImmunityBio reports promising survival and immune recovery in recurrent glioblastoma study
Sanofi advances amlitelimab toward global filings after phase 3 results in atopic dermatitis
Trevi Therapeutics reports key Phase 2b CORAL trial results for oral nalbuphine ER
Hansa Biopharma receives 2025 SwedenBIO Award
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Actuate Therapeutics advances elraglusib tablet into Phase 1/2 trial for refractory cancers
EU approves DAWNZERA for hereditary angioedema
Charles River collaborates with Gazi University on rare disease gene therapy research
Avacta secures FDA clearance for second pre|CISION oncology programme